It's not the end of the line for the drug, which Biohaven picked up in 2018, after it was shelved by AstraZeneca despite reaching the phase 2 trial stage in Parkinson's disease and MSA.

Biohaven presented positive news regarding its portfolio during its presentation at the 43 rd Annual J.P. Morgan Healthcare Conference on Monday, January 13. In a press release, the company’s CEO Vlad ...

(RTTNews) - Biohaven Ltd. (BHVN) and Merus N.V. (MRUS) announced a research collaboration and licensing agreement aimed at co-developing three innovative bispecific antibody drug conjugates (ADCs).

Biohaven Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company with a portfolio of innovative, late-stage product candidates that target neurological and psychiatric diseases.